Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,322 papers from all fields of science
Search
Sign In
Create Free Account
Canine Transitional Cell Carcinoma
A malignant neoplasm that affects dogs, arising from transitional epithelium.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Evaluation of a simulated pneumoperitoneum environment on cancer cell growth using an in vitro model with positive pressure carbon dioxide insufflation and canine transitional cell carcinoma
R. Asthana
2017
Corpus ID: 80604510
EVALUATION OF A SIMULATED PNEUMOPERITONEUM ENVIRONMENT ON CANCER CELL GROWTH USING AN IN VITRO MODEL WITH POSITIVE PRESSURE…
Expand
2016
2016
Abstract 617: Canine transitional cell carcinoma of the bladder expresses activated BRAF, but is not sensitive to vemurafenib
Belen G Hernandez
,
Kathryn E Cronise
,
+4 authors
D. Duval
2016
Corpus ID: 78274049
Transitional cell carcinoma (TCC) is the most common bladder cancer in humans and their canine companions. Canine TCCs are…
Expand
2011
2011
SIGNIFICADO PATOLÓGICO DE LA IMAGEN ULTRASÓNICA EN PEQUEÑOS ANIMALES
Antonio Moreno Boiso
,
José Hervás Rodríguez
,
F. Chacón
2011
Corpus ID: 74510655
Ultrasound is a diagnostic imaging technique safe, non invasive and does not require excessive grooming of the animal. Is used to…
Expand
2010
2010
Evaluation of an in vitro telomeric repeat amplification protocol assay to detect telomerase activity in canine urine.
A. L. McCleary-Wheeler
,
L. Williams
,
P. Hess
,
S. Suter
American Journal of Veterinary Research
2010
Corpus ID: 25270024
OBJECTIVE To evaluate the usefulness of a PCR-based telomeric repeat amplification protocol (TRAP) assay for detecting telomerase…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE